How is the healthcare sector affected by the US election results?
Comment by: Hugo Schmidt, Portfolio Manager – Healthcare Services and Tools The healthcare sector is one of the world’s most regulated, and the US election naturally has significant impact on future policy decisions. We identify a number of key points from the new administration and Congress that we believe will influence the sector: The Trump […]
Monthly summary – April
Rates and geopolitics versus earnings! Following five months of positive equity market returns, April turned out to be a somewhat harder month to navigate. The hopes for fast upcoming cuts from central banks were again dashed by stickier inflation, especially in the US, leading to yet another delay in when it could be expected. At […]
Monthly summary – March 2024
What a difference a year makes! Even though stock markets performed well during the first quarter of 2023, the beginning of 2024 has been characterized by a much more ebullient mood. The dark scenarios that dominated investment banks’ strategies in early 2023 did not materialize and investors’ appetite for risk successively increased throughout the year, […]
Rhenman & Partners strengthens its investor relations team
Rhenman & Partners hires Tom Josephson as Investor Relations Director. Tom, together with Erica von Bahr (also part of the Investor Relations team), will work with investors in Sweden and internationally. Tom’s main focus will however be on Nordic investors. Tom joins Rhenman & Partners from Brummer & Partners, where he spent nearly 18 years […]
Monthly summary – February 2024
The positive momentum persisted into February, traditionally a challenging month for markets. Contrary to expectations, stock prices increased despite rising bond yields, catching many investors by surprise. Again, the US mega caps dominated trading and performance attribution with, for example, chipmaker Nvidia rallying after a stellar report to become the third company ever to reach […]
Monthly summary – December 2023
What a difference a couple of months makes! After a dismal period in August through October, markets swung around completely in November and December as investor sentiment turned for the better. Following November, when positive market action was largely due to short covering, price movements in December reflected a generally increased risk willingness on behalf […]
Monthly summary – November 2023
The end of the rate hiking cycle and rallies in both equities and bonds! After three dismal months where investors fretted about rising bond yields, uncertainty over inflation and/or recession, and the geopolitical situation, sentiment positioning was at a year low at the end of October. In November, however, all these concerns seemed to dissipate […]
Monthly summary – October
Rising bond yields, recession fears and war! Following a dismal performance in August and September, equity markets continued down in October with a third consecutive month of falling prices. On top of the worries of “higher for longer” bond yields and the implicit risk for the overall economy going forward, the Hamas terrorist attack against […]
The complex reality of investing in Biopharma
There has been a lot of buzz recently about the new treatment methods for Alzheimer’s disease and obesity. These breakthroughs are encouraging for patients and their families and bring hope of a better quality of life. Beneath the surface of these positive readouts, we see an ever-growing number of clinical trials in various therapeutic areas […]